Fragile X Syndrome Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Zynerba Pharmaceuticals, Inc., Tetra Discovery Partners, Nova Mentis Life Science Corp, Neuren Ph

Fragile X Syndrome Pipeline constitutes 10+ key companies continuously working towards developing 12+ Fragile X Syndrome treatment therapies, analyzes DelveInsight.

Fragile X Syndrome Overview:

Fragile X syndrome (FXS) is a genetic disorder caused by mutations in the **Fragile X Messenger Ribonucleoprotein 1 (FMR1)** gene. This gene typically produces a protein called FMRP, essential for brain development. Individuals with FXS lack this protein. Also known as Martin-Bell syndrome, FXS is a non-Mendelian trinucleotide repeat disorder and the most common inherited cause of mild-to-severe intellectual disability and a leading monogenic cause of autism spectrum disorder. It accounts for about half of X-linked intellectual disability cases and is second only to trisomy 21 as a cause of mental impairment. Physical features often include a long, narrow face, prominent jaw and forehead, hyperflexible fingers, and large ears. In males, enlarged testicles may develop after puberty.

Diagnosis of FXS is performed via DNA testing from a blood sample, ordered by a doctor or genetic counselor. Testing can also identify changes in the FMR1 gene that might lead to related disorders. An FXS diagnosis can provide families with an explanation for a child's intellectual and behavioral challenges, enabling them to better manage care and support the child's development. However, genetic testing can have implications for other family members, raising ethical and emotional considerations, which makes genetic counseling an important step before testing.

Currently, there is no cure for FXS. Management focuses on treating symptoms through therapies such as speech, behavioral, sensory integration, occupational therapy, and specialized education. Early interventions are critical for improving outcomes. For example, nutritional counseling is recommended to reduce the risk of obesity, and psychiatric support may help address mood disorders, self-harm, depression, or phobias, which are more common in individuals with FXS. Medications may also be used to manage symptoms. Stimulants can address hyperactivity, impulsivity, and attention deficits, while antidepressants (e.g., bupropion, buspirone, or SSRIs/SNRIs) can treat anxiety, obsessive-compulsive behaviors, and mood disorders. However, antidepressants are more commonly prescribed for adults than for children.

Request for a detailed insights report on Fragile X Syndrome pipeline insights @ https://www.delveinsight.com/report-store/fragile-x-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Fragile X Syndrome Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Fragile X Syndrome Therapeutics Market.

Key Takeaways from the Fragile X Syndrome Pipeline Report

DelveInsight's Fragile X Syndrome pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Fragile X Syndrome treatment.
In March 2022, the European Commission granted orphan drug designation to Zygel, a transdermal gel developed by Zynerba Pharmaceuticals, for addressing behavioral symptoms in individuals with Fragile X Syndrome.
In February 2022, Ovid Therapeutics entered into an option agreement with Healx for the exclusive licensing of gaboxadol (OV101). Under this agreement, Healx acquired the option to develop and commercialize gaboxadol (OV101). Healx announced plans to explore the compound as part of a potential combination therapy for Fragile X Syndrome, as well as for other potential indications.
Key Fragile X Syndrome companies such as Zynerba Pharmaceuticals, Inc., Tetra Discovery Partners, Nova Mentis Life Science Corp, Neuren Pharmaceuticals Limited, Tetra Discovery Partners, and others are evaluating new drugs for Fragile X Syndrome to improve the treatment landscape.
Promising Fragile X Syndrome pipeline therapies in various stages of development include ZYN002, NNZ-2566, and others.

Fragile X Syndrome Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Fragile X Syndrome Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Fragile X Syndrome treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Fragile X Syndrome market.

Download our free sample page report on Fragile X Syndrome pipeline insights @ https://www.delveinsight.com/sample-request/fragile-x-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Fragile X Syndrome Emerging Drugs

ZYN002: Zynerba Pharmaceuticals, Inc.
NNZ-2566: Neurons Pharmaceuticals Limited

Fragile X Syndrome Companies

Approximately 10 or more prominent companies are actively developing therapies for Fragile X Syndrome. Among them, Zynerba Pharmaceuticals and other organizations have drug candidates currently in the most advanced stage of development, specifically Phase III clinical trials.

DelveInsight's report covers around 22+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Fragile X Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Fragile X Syndrome Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Fragile X Syndrome Therapies and Key Companies: Fragile X Syndrome Clinical Trials and advancements @ https://www.delveinsight.com/report-store/fragile-x-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Fragile X Syndrome Pipeline Therapeutic Assessment
• Fragile X Syndrome Assessment by Product Type
• Fragile X Syndrome By Stage
• Fragile X Syndrome Assessment by Route of Administration
• Fragile X Syndrome Assessment by Molecule Type

Download Fragile X Syndrome Sample report to know in detail about the Fragile X Syndrome treatment market @ Fragile X Syndrome Therapeutic Assessment @ https://www.delveinsight.com/report-store/fragile-x-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Fragile X Syndrome Current Treatment Patterns
4. Fragile X Syndrome - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Fragile X Syndrome Late-Stage Products (Phase-III)
7. Fragile X Syndrome Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Fragile X Syndrome Discontinued Products
13. Fragile X Syndrome Product Profiles
14. Fragile X Syndrome Key Companies
15. Fragile X Syndrome Key Products
16. Dormant and Discontinued Products
17. Fragile X Syndrome Unmet Needs
18. Fragile X Syndrome Future Perspectives
19. Fragile X Syndrome Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Fragile X Syndrome Pipeline Reports Offerings: https://www.delveinsight.com/sample-request/fragile-x-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.